CR20190468A - Métodos para tratar enfermedades y trastornos mediados por completo - Google Patents

Métodos para tratar enfermedades y trastornos mediados por completo

Info

Publication number
CR20190468A
CR20190468A CR20190468A CR20190468A CR20190468A CR 20190468 A CR20190468 A CR 20190468A CR 20190468 A CR20190468 A CR 20190468A CR 20190468 A CR20190468 A CR 20190468A CR 20190468 A CR20190468 A CR 20190468A
Authority
CR
Costa Rica
Prior art keywords
methods
métodos
individuo
antibody
individual
Prior art date
Application number
CR20190468A
Other languages
English (en)
Inventor
Vlasselaer Peter Van
Sandip Panicker
Graham Parry
Nancy E Stagliano
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of CR20190468A publication Critical patent/CR20190468A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CR20190468A 2017-03-14 2018-03-14 Métodos para tratar enfermedades y trastornos mediados por completo CR20190468A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US201762553059P 2017-08-31 2017-08-31
PCT/US2018/022462 WO2018170145A1 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders

Publications (1)

Publication Number Publication Date
CR20190468A true CR20190468A (es) 2019-12-17

Family

ID=61873979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190468A CR20190468A (es) 2017-03-14 2018-03-14 Métodos para tratar enfermedades y trastornos mediados por completo

Country Status (13)

Country Link
US (1) US20210115116A1 (es)
EP (1) EP3596121A1 (es)
JP (3) JP7293122B2 (es)
CN (1) CN110753701A (es)
AU (2) AU2018236267B2 (es)
BR (1) BR112019018950A2 (es)
CA (1) CA3055781A1 (es)
CR (1) CR20190468A (es)
IL (2) IL269174B1 (es)
MX (2) MX2019010994A (es)
SG (1) SG11201907583TA (es)
TW (2) TWI848905B (es)
WO (1) WO2018170145A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
BR112021011107A2 (pt) 2018-12-13 2021-12-14 Argenx Bvba Anticorpos para o fator de complemento humano c2b e métodos de uso
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
CA3159152A1 (en) * 2019-11-26 2021-06-03 Gregory A. Demopulos Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplan
FI129383B (en) * 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
MX2023001492A (es) * 2020-08-06 2023-03-08 Bioverativ Usa Inc Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
WO2023250507A1 (en) * 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
CN120344263A (zh) 2022-11-21 2025-07-18 黛安瑟斯医疗运营公司 结合c1s的抗体和其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Also Published As

Publication number Publication date
JP2023071824A (ja) 2023-05-23
TW201842931A (zh) 2018-12-16
AU2018236267A1 (en) 2019-09-26
MX2019010994A (es) 2020-12-01
JP2020511469A (ja) 2020-04-16
IL325084A (en) 2026-02-01
MX2025010483A (es) 2025-10-01
AU2018236267B2 (en) 2025-03-13
WO2018170145A1 (en) 2018-09-20
AU2025204392A1 (en) 2025-07-03
IL269174B1 (en) 2026-01-01
CN110753701A (zh) 2020-02-04
TW202513092A (zh) 2025-04-01
KR20190128676A (ko) 2019-11-18
JP2025072437A (ja) 2025-05-09
US20210115116A1 (en) 2021-04-22
BR112019018950A2 (pt) 2020-04-22
EP3596121A1 (en) 2020-01-22
JP7293122B2 (ja) 2023-06-19
TWI848905B (zh) 2024-07-21
CA3055781A1 (en) 2018-09-20
IL269174A (en) 2019-11-28
SG11201907583TA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
AR132544A2 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CO2019005236A2 (es) Métodos para tratar afecciones inflamatorias
MX2017005875A (es) Metodos para tratar enfermedades oculares.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX2020004005A (es) Terapias genicas para los trastornos lisosomales.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
CL2019000625A1 (es) Combinación de agonistas de fxr.